Lisa Deafenbaugh
Medical · Norfolk, VANPI 1326157249
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 400 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,614 and has fallen 90.8% since, to $240 in 2025. Among medical clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 400 payments — averaging $20.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$1K
- Regeneron Healthcare Solutions, Inc.$963
- GSK$871
- Sanofi$685
- AstraZeneca$614
- Grifols USA, LLC$585
- plus $3K from 20 others
What the payments were for
- Food & beverage$8,138100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 56 | $1,020 |
| Regeneron Healthcare Solutions, Inc. | 44 | $963 |
| GSK | 48 | $871 |
| Sanofi | 31 | $685 |
| AstraZeneca | 25 | $614 |
| Grifols USA, LLC | 27 | $585 |
| Takeda Pharmaceuticals U.S.A., Inc. | 33 | $576 |
| Optinose US, Inc. | 31 | $493 |
| Amgen | 16 | $475 |
| Genentech USA, Inc. | 17 | $377 |
| Novartis | 8 | $211 |
| Biocryst US Sales Co., LLC | 10 | $199 |
| Kaleo, Inc. | 10 | $197 |
| Pfizer | 7 | $182 |
| Boehringer Ingelheim | 8 | $154 |
| Pharming Healthcare, Inc. | 9 | $149 |
| Aimmune Therapeutics, Inc. | 3 | $62 |
| Hikma Pharmaceuticals USA | 3 | $62 |
| Teva Pharmaceuticals USA, Inc. | 3 | $47 |
| Octapharma USA, Inc. | 2 | $42 |
| Alk-abello, Inc | 2 | $40 |
| Blueprint Medicines Corporation | 2 | $35 |
| Incyte Corporation | 2 | $32 |
| AbbVie | 1 | $30 |
| LEO Pharma Inc. | 1 | $25 |
| Greer Laboratories, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,148 in reported general payments places this provider in the 90th percentile of 632 medical providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 12 | $53,035 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $41,081 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $10,919 |
| DuleraMometasone/Formoterol | 22 | $10,805 |
| Spiriva RespimatTiotropium Bromide | 12 | $10,296 |
| Epinephrine | 30 | $8,156 |
| QnaslBeclomethasone Dipropionate | 14 | $4,430 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 19 | $3,750 |
| Qvar RedihalerBeclomethasone Dipropionate | 12 | $2,680 |
| Olopatadine Hcl | 15 | $1,816 |
| Ipratropium Bromide | 46 | $1,660 |
| Mometasone Furoate | 36 | $1,547 |
| Azelastine Hcl | 44 | $1,439 |
| Desloratadine | 30 | $1,312 |
| Fluticasone Propionate | 28 | $876 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru | $576 | $53,03512 claims |
| GSKTrelegy Ellipta | $871 | $41,08149 claims |
| AstraZenecaBreztri Aerosphere | $614 | $10,91917 claims |
| Boehringer IngelheimSpiriva Respimat | $154 | $10,29612 claims |
| Hikma Pharmaceuticals USAEpinephrine | $62 | $8,15630 claims |
| Teva Pharmaceuticals USA, Inc.Qnasl, Qvar Redihaler | $47 | $7,11126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 632 medical providers in Virginia.
Other medical in Norfolk
- Cara DepanfilisNorfolk$17K
- Kyle VaughnNorfolk$7K
- Andrea EdwardsNorfolk$6K
- Erin GrayNorfolk$5K
- Bryan UrquhartFredericksburg$264K
- Sara VillalonaRichmond$240K
- Sarah SafaLansdowne$171K
- Waseem GarbiaFairfax$114K
- Rana HassanAshburn$54K
- Brian LamFalls Church$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.